Vaccinating children: The pros and cons

Area of Science:

• Immunology
• Public Health
• Pediatrics

Background:

• COVID-19 vaccination in children sparked debate due to generally mild clinical presentations.
• Adolescent vaccination decisions were driven by the need to reduce transmission to other age groups.
• The collective benefit of vaccinating 5-to-12-year-olds against COVID-19 remains less clear due to lower contamination rates.

Purpose of the Study:

• To evaluate the efficacy and safety of COVID-19 vaccines in adolescents and younger children.
• To assess the public health rationale for pediatric COVID-19 vaccination, focusing on transmission reduction.
• To determine the individual benefits of vaccination for children, considering somatic health, schooling, and mental well-being.

Main Methods:

• Review of vaccine efficacy and safety data in adolescent populations.
• Analysis of the impact of COVID-19 variants, such as Omicron, on vaccine effectiveness in children.
• Evaluation of immunogenicity data for different pediatric age groups, including dose-response relationships.

Main Results:

• COVID-19 vaccine efficacy and safety were clearly demonstrated in adolescents, offering better immunity than in young adults.
• For 5-to-12-year-olds, the effect on non-severe infections and transmission during the Omicron variant predominance was not fully determined.
• A 3 µg dose of mRNA vaccine in children under 5 years achieved immunogenicity similar to that in 16-to-25-year-olds.

Conclusions:

• Adolescent COVID-19 vaccination is supported by demonstrated efficacy, safety, and public health benefits in reducing transmission.
• The decision to vaccinate younger children involves balancing collective benefits against individual factors like health, schooling, and mental health.
• Pediatric COVID-19 vaccination strategies require ongoing evaluation, especially concerning variant circulation and specific age group benefits.